obesity drug glp-1 news today weight loss drugs leave users low on key nutrients, study finds The GLP-1 Access Gap: Mapping

While industry proponents will frame Ozempic, Rybelsus and Wegovy as three new products and inventions (or innovations), all three rely on the exact same active ingredient

doi: 10.1016/j.metop.2022.100220

[DOI] [PubMed] [Google Scholar] 45.Buysschaert M., Baeck M., Preumont V., Marot L., Hendrickx E., Van Belle A., Dumoutier L

For obesity treatment in the UK, NHS-commissioned semaglutide 2.4mg (Wegovy) is limited to a maximum of 2 years through specialist weight management services, with specific BMI thresholds (including lower thresholds for some ethnic groups)

Key Takeaways MedVi charges $199$299/month for compounded GLP-1 medications through its online telehealth platform, with no insurance accepted Several alternatives cost less: Enhance.MD starts at $49 for the first month, Yucca Health from $169/month, and T-Mates offers no-hidden-fee flat pricing Insurance-friendly options exist: Found Health (free insurance check) and PlushCare work with health insurance, potentially saving $50$200+/month All providers offer compounded or brand-name GLP-1s: Semaglutide and tirzepatide are the most commonly prescribed across platforms Research-grade peptides offer another path: For laboratory and research use, GLP-1 compounds are available at significantly lower cost MedVi has grown into one of the more visible telehealth platforms for GLP-1 weight loss prescriptions, serving over 500,000 patients through its online portal and generating $1.6 billion in first-year sales